Treace Medical Concepts Sees Revenue Growth Amidst Widening Quarterly Loss

Ticker: TMCI · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: mixed

Topics: Medical Devices, Orthopedics, Bunion Correction, Revenue Growth, Net Loss, Cash Burn, Operating Expenses, SEC Filing, 10-Q

Related Tickers: TMCI

TL;DR

**TMCI is growing revenue but bleeding cash, making it a risky bet until they show a clear path to profitability.**

AI Summary

Treace Medical Concepts, Inc. (TMCI) reported revenue of $50.214 million for the three months ended September 30, 2025, an 11.4% increase from $45.086 million in the same period of 2024. For the nine months ended September 30, 2025, revenue grew to $150.171 million, up 6.8% from $140.649 million in 2024. Despite revenue growth, the company experienced a net loss of $16.288 million for the quarter, compared to a net loss of $15.360 million in Q3 2024, and a net loss of $49.608 million for the nine-month period, an improvement from a $55.242 million net loss in the prior year. Operating expenses increased to $55.382 million for the quarter, up from $51.266 million, primarily driven by higher sales and marketing expenses of $34.421 million. Cash and cash equivalents decreased significantly from $11.350 million at December 31, 2024, to $7.686 million at September 30, 2025, with net cash used in operating activities totaling $7.944 million for the nine months. The company continues to invest in its Lapiplasty 3D Bunion Correction System and expanded product offerings, while managing increased legal costs related to intellectual property lawsuits initiated in October 2024 and May 2025.

Why It Matters

TMCI's continued revenue growth, particularly with its Lapiplasty system, signals strong market adoption for its specialized bunion correction solutions, which is positive for investors looking for growth in the medical device sector. However, the persistent net losses and increasing operating expenses, especially in sales and marketing, raise concerns about profitability and cash burn, impacting investor confidence. For employees, sustained growth could mean job security and expansion, but financial losses might lead to cost-cutting measures. Customers benefit from advanced surgical options, but the company's financial health could indirectly affect product development or support. In a competitive market, TMCI's ability to convert revenue into profit will determine its long-term viability against rivals offering similar or alternative orthopedic solutions.

Risk Assessment

Risk Level: high — The company reported a net loss of $16.288 million for the quarter and $49.608 million for the nine months ended September 30, 2025, indicating ongoing unprofitability. Cash and cash equivalents decreased by $3.664 million during the nine-month period, from $11.350 million to $7.686 million, with $7.944 million used in operating activities, highlighting significant cash burn and potential liquidity concerns.

Analyst Insight

Investors should closely monitor TMCI's next few quarters for signs of improved cost control and a clear path to profitability, especially given the increasing operating expenses and cash burn. Consider holding off on new investments until there's evidence of reduced net losses or positive operating cash flow, as the current financial trajectory presents significant risk.

Financial Highlights

debt To Equity
0.60
revenue
$50.214M
operating Margin
-10.7%
total Assets
$196.591M
total Debt
$53.529M
net Income
-$16.288M
eps
Not Disclosed
gross Margin
79.1%
cash Position
$7.686M
revenue Growth
+11.4%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$50.214M+11.4%

Key Numbers

Key Players & Entities

FAQ

What were Treace Medical Concepts' revenues for the third quarter of 2025?

Treace Medical Concepts, Inc. reported revenues of $50.214 million for the three months ended September 30, 2025. This represents an increase from $45.086 million in the same period of 2024.

Did Treace Medical Concepts achieve profitability in Q3 2025?

No, Treace Medical Concepts, Inc. did not achieve profitability in Q3 2025. The company reported a net loss of $16.288 million for the three months ended September 30, 2025, which is a wider loss compared to $15.360 million in Q3 2024.

How much cash and cash equivalents did TMCI have as of September 30, 2025?

As of September 30, 2025, Treace Medical Concepts, Inc. had $7.686 million in cash and cash equivalents. This is a decrease from $11.350 million reported at December 31, 2024.

What were the key drivers of operating expenses for Treace Medical Concepts in the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, total operating expenses for Treace Medical Concepts, Inc. were $167.583 million. The largest component was sales and marketing expenses at $103.627 million, followed by general and administrative expenses at $48.216 million.

What is the Lapiplasty 3D Bunion Correction System?

The Lapiplasty 3D Bunion Correction System is a patented product pioneered by Treace Medical Concepts, Inc. It is a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of bunion deformity and secure the unstable joint, addressing the root cause of bunions.

What is Treace Medical Concepts' strategic outlook regarding its product offerings?

Treace Medical Concepts, Inc. aims to advance the standard of care for surgical management of bunion and related midfoot deformities. The company has expanded its product offerings beyond the Lapiplasty system to become a comprehensive bunion solutions company and further penetrate the bunion market opportunity.

What are the primary risks highlighted in Treace Medical Concepts' 10-Q filing?

The 10-Q filing highlights risks including extensive competition, new product introductions from competitors, the ability to control and reduce expenses, dependence on the Lapiplasty system, inflationary pressures, changes in interest rates, and the impact of ongoing litigation related to intellectual property.

How has Treace Medical Concepts' net loss per share changed?

For the three months ended September 30, 2025, Treace Medical Concepts' net loss per share was $(0.26), compared to $(0.25) in the same period of 2024. For the nine months ended September 30, 2025, the net loss per share improved to $(0.79) from $(0.89) in the prior year period.

What is the company's current status regarding its SEC filing requirements?

Treace Medical Concepts, Inc. indicated by check mark that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. It also submitted every Interactive Data File required by Rule 405 of Regulation S-T.

What is the impact of share-based compensation on Treace Medical Concepts' financials?

Share-based compensation expense was a significant non-cash adjustment, totaling $26.268 million for the nine months ended September 30, 2025. This expense contributes to the net loss but is added back when calculating net cash provided by (used in) operating activities.

Risk Factors

Industry Context

Treace Medical Concepts operates in the competitive orthopedic medical device market, specifically focusing on foot and ankle procedures. The industry is characterized by innovation, significant R&D investment, and a complex regulatory landscape. Key trends include the adoption of minimally invasive techniques and advanced imaging technologies, such as 3D correction systems, which TMCI's Lapiplasty system represents.

Regulatory Implications

As a medical device company, Treace Medical Concepts is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, product approvals, and post-market surveillance is critical. Any changes in regulatory requirements or enforcement could impact product development timelines, market access, and operational costs.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically operated at a loss, with the deficit increasing in the current period.)
Operating lease right-of-use assets
Assets recognized by lessees under IFRS 16 and ASC 842, representing the right to use an underlying asset for the lease term. (Reflects the company's long-term rental commitments for facilities or equipment.)
Additional paid-in capital
The amount of capital that shareholders have paid to the company for stock in excess of its par value. (Shows the total capital raised from stock issuance beyond the nominal value of the shares.)
Net cash used in operating activities
The amount of cash a company has spent on its operations over a period. A negative number indicates cash outflow. (Highlights the company's cash burn rate from its core business operations.)

Year-Over-Year Comparison

Compared to the prior year, Treace Medical Concepts has demonstrated revenue growth, with Q3 2025 revenue increasing by 11.4% to $50.214 million and nine-month revenue up 6.8% to $150.171 million. However, this top-line growth has been accompanied by an increase in net loss for the quarter ($16.288 million vs. $15.360 million) and a concerning decline in cash and cash equivalents from $11.350 million to $7.686 million. New risks have emerged, notably increased legal costs from intellectual property lawsuits initiated in late 2024 and mid-2025, alongside rising operating expenses, particularly in sales and marketing.

Filing Stats: 4,436 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-11-06 16:14:26

Key Financial Figures

Filing Documents

: Financial Information

Part I: Financial Information Item 1. Condensed Financial Statements 3 Condensed Balance Sheets 3 Condensed Statements of Operations and Comprehensive Loss 4 Condensed Statements of Stockholders' Equity 5 Condensed Statements of Cash Flows 6 Notes to Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

: Other Information

Part II: Other Information Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 28

Signatures

Signatures 29 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS As used in this Quarterly Report on Form 10-Q ("Quarterly Report"), unless expressly indicated or the context otherwise requires, references to "Treace Medical Concepts," "we," "us," "our," or the "Company," refer to Treace Medical Concepts, Inc. This Quarterly Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as codified in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "slated," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the expected use of our products by physicians; the expected growth of our business and our organization and expected improvements in profitability, cash usage, and other financial results; our ability to increase market share and effectively respond to and mitigate the impact of challenges in the current market environment, including the extensive competition in our industry and new product introductions from other industry participants, including in both the Lapidus

–FINANCI AL INFORMATION

PART I–FINANCI AL INFORMATION

Condensed Financial Sta tements

Item 1. Condensed Financial Sta tements. TREACE MEDICAL CONCEPTS, INC. Condensed Bal ance Sheets (in thousands, except share and per share amounts) (unaudited) September 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 7,686 $ 11,350 Marketable securities, short-term 49,730 64,327 Accounts receivable, net of allowance for credit losses of $ 1,505 and $ 1,326 as of September 30, 2025 and December 31, 2024, respectively 32,959 40,803 Inventories 41,424 39,255 Prepaid expenses and other current assets 6,198 5,667 Total current assets 137,997 161,402 Property and equipment, net 29,970 25,953 Intangible assets, net of accumulated amortization of $ 2,138 and $ 1,425 as of September 30, 2025 and December 31, 2024, respectively 7,362 8,075 Goodwill 12,815 12,815 Operating lease right-of-use assets 7,833 8,442 Other non-current assets 614 407 Total assets $ 196,591 $ 217,094 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 16,103 $ 10,522 Accrued liabilities 7,315 7,197 Accrued commissions 6,215 10,121 Accrued compensation 7,172 6,575 Other liabilities 4,103 510 Total current liabilities 40,908 34,925 Long-term debt, net 53,529 53,306 Operating lease liabilities, net of current portion 12,930 15,934 Other long-term liabilities 37 37 Total liabilities 107,404 104,202 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.001 par value, 5,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 300,000,000 shares authorized; 63,846,382 and 62,385,101 shares issued as of September 30, 2025 and December 31, 2024, respectively 64 62 Additional paid-in capital 329,746 303,004 Accumulated deficit

View on Read The Filing